Detalhe da pesquisa
1.
AI-based CT Body Composition Identifies Myosteatosis as Key Mortality Predictor in Asymptomatic Adults.
Radiology
; 307(5): e222008, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37191484
2.
Muscle fat content is strongly associated with NASH: A longitudinal study in patients with morbid obesity.
J Hepatol
; 75(2): 292-301, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33865909
3.
The Liver in COVID-19-Related Death: Protagonist or Innocent Bystander?
Pathobiology
; 88(1): 88-94, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33108789
4.
Activation of brown adipose tissue enhances the efficacy of caloric restriction for treatment of nonalcoholic steatohepatitis.
Lab Invest
; 99(1): 4-16, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30258096
5.
Reactive cholangiocytes differentiate into proliferative hepatocytes with efficient DNA repair in mice with chronic liver injury.
J Hepatol
; 70(6): 1180-1191, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30794890
6.
Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis.
J Viral Hepat
; 26(3): 337-349, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30421537
7.
Comparison of Sanger sequencing for hepatitis C virus genotyping with a commercial line probe assay in a tertiary hospital.
BMC Infect Dis
; 19(1): 738, 2019 Aug 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-31438880
8.
Tamoxifen-induced hepatotoxicity caused by drug interaction with direct-acting antiviral agents for hepatitis C.
J Oncol Pharm Pract
; 25(8): 2038-2040, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-30563414
9.
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.
Clin Gastroenterol Hepatol
; 16(3): 417-426, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28951228
10.
Genetic and phylogenic characterization of hepatitis B virus in the eastern part of the Democratic Republic of Congo.
J Med Virol
; 90(2): 250-254, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28460156
11.
Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen.
Antimicrob Agents Chemother
; 61(12)2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28971875
12.
Defective adaptive thermogenesis contributes to metabolic syndrome and liver steatosis in obese mice.
Clin Sci (Lond)
; 131(4): 285-296, 2017 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27803297
13.
Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease.
Liver Int
; 37(9): 1304-1313, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28135777
14.
Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection.
BMC Gastroenterol
; 17(1): 26, 2017 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28187751
15.
Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant.
Ann Hepatol
; 16(3): 375-381, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28425407
16.
Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.
J Hepatol
; 64(2): 301-307, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26476290
17.
Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial.
Clin Immunol
; 169: 16-27, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27236001
18.
Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet
; 384(9941): 414-26, 2014 Aug 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-24907224
19.
ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.
Gastroenterology
; 147(2): 359-365.e1, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24818763
20.
Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.
Gastroenterology
; 146(3): 744-753.e3, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24316262